31 results about "Intraarticular Injections" patented technology

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

The present invention relates to a composition for intra-articular injection in dogs or cats, which is used to treat or ameliorate arthritis or reduce mechanical friction at joint sites by physical repair when injected into the joint cavity of dogs or cats. The present invention also relates to a method for administering a composition for intra-articular injection in dogs or cats, which is used to treat or ameliorate arthritis or reduce mechanical friction at joint sites by physical repair when injected into the joint cavity of dogs or cats. The composition of the present invention is administered so that the dosage of polynucleotide sodium is 2 to 3 mg, preferably 2.5 to 3 mg, per kg of body weight of the dog or cat.

The present invention relates to a hydrogel composition for intra-articular administration, which is easily injected into the human body, and use thereof for supplementing joint synovial fluid, supplementing viscosity, and preventing or treating intra-articular lesions. The hydrogel composition according to the present invention can improve the gelation temperature, viscosity, biodegradability, and tissue support capability of hyaluronic acid and, at the same time, can improve practitioner convenience and patient compliance due to the reduced injection pressure thereof. In addition, the hydrogel composition can increase the effect of ameliorating intra-articular lesions when co-administered with stem cells or exosomes, and thus can have various applications in medical devices and pharmaceutical fields for the purpose of cartilage regeneration and intra-articular lesion treatment.

The present invention relates to a pharmaceutical composition suitable for intraarticular injection comprising an anesthetic and an immediate release or controlled release dosage form comprising colchicine. It also relates to a pharmaceutical composition in powder form comprising an anesthetic and an immediate release or controlled release dosage form comprising colchicine wherein the controlled release dosage form comprising colchicine is in particulate form. It also relates to a pharmaceutical composition in powder form comprising an anesthetic and an immediate release or controlled release dosage form comprising colchicine wherein the controlled release dosage form comprising colchicine is in particulate form, relates to a pharmaceutical composition, to a kit and to the use of said pharmaceutical composition or kit in the treatment of crystal-related and non-crystal-related acute inflammatory arthritis, in particular crystal-related arthropathy or sudden or acute forms of tendinitis and bursitis, by intra-articular injection of said pharmaceutical composition into the joint, and to the use of said pharmaceutical composition or kit in the treatment of crystal-related and non-crystal-related acute inflammatory arthritis, in particular crystal-related arthropathy or sudden or acute forms of tendinitis and bursitis, and to provide pain relief immediately and throughout the treatment.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

The present invention relates to pharmaceutical composition under the form of a suspension comprising controlled release microparticles comprising colchicine for use in the treatment of crystal-associated and non-crystal associated acute inflammatory arthritis by intra-articular injection into a joint of said pharmaceutical composition, wherein the microparticles have a mean particle size greater than 10 pm, wherein the time required to release 80% by weight of the colchicine in the microparticles is greater than 1 day and may reach 15 days, wherein the colchicine is present in a concentration ranging from 2.5 to 2500 pg per ml of suspension and wherein the pharmaceutical composition has a volume ranging from 0.1 ml to 5 ml.

The present invention provides microparticles that induce the migration of multipotent stem cells to the anatomical site of the microparticles. Various release profiles are demonstrated that depend upon the relative concentration of alginate in the chemokine-loaded microparticle. Local administration and / or intraarticular injection of the microparticles are useful in conditions such as osteoarthritis. Targeted systemic delivery of the alginate chemokine microparticles to distant anatomical sites subjected to autoimmune disease symptomology can be performed by encapsulation within liposomes having targeting ligands. Consequently, upon the creation of the appropriate chemokine gradient, multipotent stem cells will migrate to the distant anatomical site where the liposomes are attached.

The present invention relates to a composition for intra-articular use for the treatment of osteoarthritis (OA), comprising cross-linked hyaluronic acid or a salt or derivative thereof, clodronic acid or an equivalent salt thereof, and acetate buffer.

The application belongs to the technical field of medical decision support, and discloses a knee joint postoperative distal deep vein thrombosis prediction system; by acquiring multi-dimensional parameters such as coagulation function, metabolic function, inflammation ratio index and intra-articular injection history, the sodium hyaluronate injection history is converted into an articular lesion severity score, an inflammation-coagulation coupling characteristic vector and a metabolic disturbance correction model are innovatively constructed, and the synergistic effect among multiple systems is captured. A penalty regression model with cross-validation is used for sparse prediction factor screening, redundant variables are screened out through a regularization path shrinkage technology, and key prediction factors are reserved. Finally, an individualized thrombosis risk probability nomogram is constructed, and the prediction accuracy is verified through resampling calibration. The application realizes the multi-system integration of inflammation, coagulation, metabolism and joint degeneration factors, converts the complex statistical model into a clinically friendly tool, and optimizes the postoperative thrombosis prevention and control strategy.

The invention discloses an application of sulphaguanidine in preparation of a medicine for treating osteoarthritis. According to the invention, the obvious curative effect of the sulfadimidine (sulfadimidine) in the aspect of treating the osteoarthritis (OA) through intraarticular injection is confirmed for the first time; research results show that the sulphaguanidine not only can remarkably relieve the symptoms of osteoarthritis, but also can improve the metabolic function of cartilage cells, so that the progress of arthritis is slowed down. Traditional treatment methods mainly include intraarticular injection of anesthetic drugs, joint lubrication drugs (such as sodium hyaluronate), glucocorticoid and platelet rich plasma (PRP). However, these methods have limitations, such as significant effects in short periods but may cause side effects in long-term use. As a novel treatment means, sulphaguanidine not only has a good curative effect, but also has small side effects, and provides a new thought for drug treatment of osteoarthritis.

A method of treating a subject having an articular disorder by administration of a long-acting liposomal composition. A preferred liposomal composition includes a phosphatidylcholine as the sole active ingredient, wherein the phosphatidylcholine is selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, N-palmitoyl-D-erythro-sphingosylphosphorylcholine, and a combination thereof. A preferred administration is by a single intra-articular injection once or every 4 to 12 months to afford pain relief and / or reduction of irritation in the joint of the subject.

This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.

A method of treating a subject having an articular disorder by administration of a long-acting liposomal composition. A preferred liposomal composition includes a phosphatidylcholine as the sole active ingredient, wherein the phosphatidylcholine is selected from the group consisting of 1,2-dimyristoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, N-palmitoyl-D-erythro-sphingosylphosphorylcholine, and a combination thereof. A preferred administration is by a single intra-articular injection once or every 4 to 12 months to afford pain relief and / or reduction of irritation in the joint of the subject.

The present disclosure relates to an ultrasound guided intraarticular administration of a combination of a composition comprising pooled mesenchymal stromal cells, and mid molecular weight hyaluronic acid for treatment of osteoarthritis. The disclosure also provides methods for increasing levels of anti-inflammatory marker and decreasing levels of disease progression marker in a human subject suffering from osteoarthritis through the use of the said combination. The present disclosure accordingly also relates to a kit comprising the said composition and the hyaluronic acid as such for the said use and treatment.

The invention relates to a liquid pharmaceutical concentrate comprising or essentially consisting of Resiniferatoxin in an amount of less than 3.20 μg, preferably at most 900 ng, more preferably at most 700 ng and ethanol. The composition according to the invention is particularly useful for the treatment of pain due to knee osteoarthritis. Prior to administration, the concentrate is diluted with a dilution liquid, preferably an aqueous dilution liquid, thereby obtaining a diluted composition, preferably a diluted solution. Said diluted composition or a partial volume thereof is subsequently administered as dose unit, preferably by intraarticular injection into the knee.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

This invention relates to alginate–pectin polymer-based quercetin microspheres as an anti-inflammatory drug delivery system for intra-articular application in osteoarthritis. The microspheres were prepared using an ionic gelation method through an ionotropic aerosolization technique, in which a solution of quercetin and alginate–pectin polymer with a total concentration of approximately 3% was sprayed into a calcium chloride (CaCl₂) solution using a pressure of approximately 40 psi and a spray distance of approximately 8 cm. The alginate–pectin ratios used included 1:1 and 1:2, with the addition of lyophilisate in the form of lactose or maltodextrin during the lyophilization process. The results showed that increasing the pectin fraction and the use of maltodextrin increased drug loading and entrapment efficiency of quercetin, while a 1:1 ratio produced microspheres with a more compact structure and higher yield.The present invention provides a formulation and method for producing quercetin microspheres with adjustable properties, thus potentially being used as a controlled-release intra-articular injectable preparation for the therapy of joint inflammation.

The present invention relates to a pharmaceutical composition in the form of a sterile and injectable dosage form comprising a controlled release dosage form comprising colchicine for use in the treatment of arthropathy, such as osteoarthritis, aggressive hand osteoarthritis and any other type of chondropathy, by intraarticular injection of said pharmaceutical composition into the joint, such as osteoarthritis, aggressive hand osteoarthritis, and any other type of chondropathy. The present invention relates to colchicine, in particular colchicine, and / or for the treatment of pain-related arthropathy, and / or for the protection of joints, bones and / or cartilages, in which 80% by weight of colchicine is released for more than one month, and in which colchicine is present in a concentration of 1 to 27.5 mg per mL of sterile and injectable dosage, and / or for the treatment of pain-related arthropathy, and / or for the protection of joints, bones and / or cartilages. The invention also relates to a sterile and injectable pharmaceutical composition comprising a controlled release dosage form containing colchicine, which has a suitable in vitro dissolution characteristic. The invention also relates to a formulation in powder form and to a pharmaceutical composition in sterile and injectable dosage form form suitable for intra-articular injection comprising colchicine, in particulate form comprising a polymer matrix, and to a related kit or article of manufacture.

The invention relates to a reconstitutable solid pharmaceutical composition comprising or essentially consisting of Resiniferatoxin in an amount of less than 3.20 μg, preferably at most 900 ng, more preferably at most 500 ng; optionally, a surfactant; and optionally, a buffer. The composition according to the invention is particularly useful for the treatment of pain due to knee osteoarthritis. Prior to administration, the solid composition is reconstituted with a reconstitution liquid thereby obtaining a reconstituted composition. Said reconstituted composition or a partial volume thereof is subsequently administered as dose unit, preferably by intraarticular injection into the knee.

This invention discloses the application of sulfadimidine in the preparation of drugs for treating osteoarthritis. This invention is the first to demonstrate the significant efficacy of intra-articular injection of sulfadimidine in the treatment of osteoarthritis (OA); the results show that sulfadimidine can not only significantly relieve the symptoms of osteoarthritis but also improve the metabolic function of chondrocytes, thereby slowing the progression of arthritis. Traditional treatment methods mainly include intra-articular injection of anesthetic drugs, joint lubricants (such as sodium hyaluronate), glucocorticoids, and platelet-rich plasma (PRP). However, these methods each have limitations, such as significant short-term effects but potential long-term side effects. Sulfamidine, as a novel treatment method, not only has good efficacy but also fewer side effects, providing a new approach to the drug treatment of osteoarthritis.

The invention relates to a pharmaceutical dosage form for injection, preferably intraarticular injection into a knee, comprising or essentially consisting of (i) Resiniferatoxin; preferably at a dose within the range of from 50 to 900 ng, preferably less than 500 ng; (ii) water; (iii) an organic solvent; preferably ethanol; (iv) a surfactant; preferably D-α-tocopherol polyethylene glycol succinate (TPGS); (v) optionally, a buffer; and (vi) optionally, one or more inorganic salts; wherein the weight content of the water is greater than the weight content of the organic solvent. The invention further relates to a liquid pharmaceutical dosage form comprising Resiniferatoxin at a dose within the range of from 50 to 900 ng, preferably less than 500 ng for use in the treatment of knee joint pain, preferably osteoarthritic knee joint pain, by intraarticular administration, preferably intraarticular injection. The invention further relates to administration regimens for the treatment of knee joint pain, preferably osteoarthritic knee joint pain, by intraarticular administration, preferably intraarticular injection of liquid pharmaceutical dosage forms comprising Resiniferatoxin at a dose within the range of from 50 to 900 ng, preferably less than 500 ng.

The present invention relates to a pharmaceutical composition suitable for intra-articular injection, comprising an anesthetic and an immediate-release or controlled-release dosage form containing colchicine. Furthermore, the present invention relates to a pharmaceutical composition in powder form comprising an anesthetic and an immediate-release or controlled-release dosage form containing colchicine, wherein the controlled-release dosage form containing colchicine is in the form of fine particles. Furthermore, the present invention relates to a pharmaceutical composition in powder form comprising an anesthetic and an immediate-release or controlled-release dosage form containing colchicine, wherein the controlled-release dosage form containing colchicine is in the form of fine particles, a kit, and the use of the pharmaceutical composition or kit in the treatment of crystal-associated acute inflammatory arthritis and amorphous acute inflammatory arthritis, particularly crystal-associated arthropathy or erythema or acute type tendinitis and capsulitis, by intra-articular injection of the pharmaceutical composition into the joint, providing immediate and overall treatment-long analgesia.

The invention discloses an application of amiodarone or amiodarone salt in preparation of an intra-articular injection medicine for treating knee osteoarthritis pain, and also discloses a pharmaceutical composition containing amiodarone or amiodarone salt. The amiodarone articular cavity injection is developed, and the curative effect on pain symptoms caused by knee osteoarthritis is definite; the cost is low, the tolerance is good, and the medicine is accepted by patients. The invention develops a new application of the traditional arrhythmia medicine amiodarone, is safe under an effective dose, and has no obvious side effect on articular cartilage.

The invention relates to a reconstitutable solid pharmaceutical composition comprising or essentially consisting of Resiniferatoxin in an amount of less than 3.20 µg, preferably at most 900 ng, more preferably at most 500 ng; optionally, a surfactant; and optionally, a buffer. The composition according to the invention is particularly useful for the treatment of pain due to knee osteoarthritis. Prior to administration, the solid composition is reconstituted with a reconstitution liquid thereby obtaining a reconstituted composition. Said reconstituted composition or a partial volume thereof is subsequently administered as dose unit, preferably by intraarticular injection into the knee.

The present invention relates to a hydrogel composition for joint cavity administration, which is easy to inject into the human body, and uses thereof for preventing or treating lesions in joints, and regenerating cartilage. The hydrogel composition according to the present invention gels in the body and slowly decomposes at a lesion site for two to six months to supplement a defective site, and slowly releases active ingredients such as stem cells or exosomes to the lesion site, thereby inducing continuous inflammation inhibition and cartilage regeneration effects. Therefore, the composition of the present invention can be variously used in the fields of medical devices and pharmaceuticals for the purpose of regenerating cartilage and treating lesions in joints.

The invention relates to a liquid pharmaceutical concentrate comprising or essentially consisting of Resiniferatoxin in an amount of less than 3.20 µg, preferably at most 900 ng, more preferably at most 700 ng and ethanol. The composition according to the invention is particularly useful for the treatment of pain due to knee osteoarthritis. Prior to administration, the concentrate is diluted with a dilution liquid, preferably an aqueous dilution liquid, thereby obtaining a diluted composition, preferably a diluted solution. Said diluted composition or a partial volume thereof is subsequently administered as dose unit, preferably by intraarticular injection into the knee.

The invention relates to a composition comprising mitochondria isolated from umbilical cord mesenchymal stem cells (UC-MSCs), which are specifically enriched and prepared for therapeutic use in osteoarthritis (OA). Mitochondria are isolated from UC-MSC cultures in earlier passages (P3- P7). The isolated mitochondria are suspended in a biocompatible carrier suitable for intra-articular injection. The invention further encompasses a method for treating and / or regenerating and / or ameliorating OA in a subject by administering the composition to the affected joint.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.